Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CHD1 divergent transcript (CHD1-DT), also known as LOC100289230, is an uncharacterized human gene annotated in genomic databases. The term "divergent transcript" suggests it is a non-coding RNA (likely a lncRNA) transcribed in proximity to the CHD1 (chromodomain helicase DNA-binding protein 1) gene, but not encoding the CHD1 protein. There are no available data linking CHD1-DT to therapeutic mechanisms, drug interaction, or established roles in disease, and its biological function remains undefined in peer-reviewed literature[2]. Notes & clarifications: - There is substantial information on the protein-coding gene CHD1[1][5], a chromatin remodeler with roles in transcription, chromatin modification, and certain developmental and stem cell processes. However, CHD1 divergent transcript is a distinct, non-coding gene with no known target or effector function. - The term "divergent transcript" often refers to non-coding or regulatory RNA located near and transcribed in the opposite direction from a known gene (here, CHD1), but such loci are usually not drug targets unless specific function is proven. In summary, CHD1-DT/LOC100289230 is not a current therapeutic or functional target, and is likely listed due to its genomic proximity and divergent transcription relative to the protein-coding CHD1 gene. There is no data supporting a role as a target, biomarker, or involvement in disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CHD1 divergent transcript (CHD1-DT).